Acuta Capital Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Acuta Capital Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.2M	Buy	215,652 +23,892	+12%	+$433K	2.93%	12
2026 Q1	$3.57M	Buy	191,760 +132,480	+223%	+$2.19M	2.52%	12
2025 Q4	$781K	Buy	+59,280	New	+$699K	0.53%	23
2023 Q1	–	Sell	-93,500	Closed	-$982K	–	39
2022 Q4	$982K	Buy	+93,500	New	+$831K	0.6%	27

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acuta Capital Partners's MLTX Position: Q2 2026 in Review

Acuta Capital Partners increased its MoonLake Immunotherapeutics (MLTX) stake by 12% in Q2 2026, buying an estimated $433K and bringing the position to 215,652 shares worth $4.2M. The position accounts for 2.93% of the portfolio, ranked #12.

Acuta Capital Partners first reported a position in MLTX in Q4 2022 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Acuta Capital Partners held 215,652 shares of MoonLake Immunotherapeutics worth $4.2M as of Q2 2026.
Acuta Capital Partners bought 23,892 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $433K.
MoonLake Immunotherapeutics made up 2.93% of Acuta Capital Partners's portfolio in Q2 2026, its #12 holding.
Acuta Capital Partners first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 4 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.